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Abstract
Introduction: Substantial data has shown that the lectican group of chondroitin sulfate proteoglycans are involved
in inhibition of axonal plasticity in response to injury in the central nervous system. Increasing evidence indicates
that lecticans may also play a role in synaptic plasticity related to memory, especially associated with aging. A
recent study has shown that lectican expression is elevated at a young age in the APPswe/PS1dE9 mouse model
and Alzheimer’s disease (AD) and hippocampal treatment with chondroitinase ABC reversed a loss of contextual
fear memory and restored long-term potentiation. The purpose of this study was to examine the presence of a
synaptic lectican in AD tissue, determine if amyloid-β (Aβ) binds to lecticans purified from brain tissue, and examine
how treatment of the same AD model with chondroitinase ABC would influence plaque burden and the density of
the synaptic marker synaptophysin around plaques.
Results: In human superior frontal gyrus, levels of the brain-specific lectican, brevican, were significantly elevated in
AD compared to non-cognitively impaired subjects, with a trend toward an increase in tissue from subjects with
mild cognitive impairment. In vitro immunoprecipitation studies showed that brevican binds to oligomeric and
fibrillar Aβ1-42, and less so to monomeric Aβ1-42. Intrahippocampal injection of 15 months APPswe/PS1dE9 mice
with chondroitinase ABC resulted in a reduction of Aβ burden in the stratum lacunosum moleculare and a reversal
of the loss of synaptic density surrounding plaques in the same region.
Conclusions: It is possible that lecticans, particularly brevican, inhibit synaptic plasticity in this model of AD. Since
the hippocampus undergoes changes in synaptic plasticity early in the disease process, it could be possible that
removal of lecticans or inhibition of their signaling pathways could prolong plasticity in patients early in the disease
process, and delay cognitive decline of AD progression.
Introduction
Numerous molecular events occur in the post-synaptic
density of an excitatory synapse in response to a train of
pre-synaptic action potentials. These include a change in
transmission sensitivity and alterations in the structure of
the dendritic spine, and these interrelated functions are
essential for the formation and other aspects of memory
[1–3]. While activation of NMDA receptors and increases
in Ca++ in the post-synaptic density are key components
of this process [4], additional factors contribute. One of
these factors is the presence of peri-synaptic extracellular
matrix (ECM), a lattice of chondroitin sulfate (CS)-bearing
proteoglycans (PGs), termed lecticans (aggrecan, brevican,
neurocan, and versican), bound to hyaluronic acid near
their N-terminus and tenascin-R near their C-terminus
[5]. Brevican is a lectican expressed at the synapse as it
was originally discovered as a synapse-associated protein
[6]. Lecticans, as part of this lattice are thought to provide
stability to synapses, and inhibit functional and structural
synaptic plasticity including the growth of dendritic spines
and reversal of evoked field post-synaptic potentials. The
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majority of data that supports the role of lecticans in plas-
ticity is derived from studies that injected the bacterial en-
zyme chondroitinase ABC (ChABC) into the brain.
ChABC treatment results in removal of CS chains from
lectican core proteins (and other CS-bearing PGs). These
studies demonstrated that removal of CS chains stimu-
lated plasticity as measured by functional outcomes in-
cluding visual ocular dominance [7, 8], fear memory [9]
and other forms of learning [10]. These findings suggest
that the ECM lattice present at the synapse could be a
therapeutic target for neurological disorders with dimin-
ished synaptic plasticity.
Alzheimer’s disease (AD) is the most common cause of
dementia, and the earliest functional deficit most often as-
sociated with the disease is a loss of memory [11]. Synap-
tic alterations also occur early in AD progression; synaptic
loss is observed prior to neuronal cell death, and the loss
of synapses in the outer molecular layer of the hippocam-
pal dentate gyrus is more highly correlated with cognitive
impairment than other classical AD pathology including
neurofibrillary tangles and senile plaques [12–15]. How-
ever, some data supports a role for both tau in neurofibril-
lary tangles, and Aβ surrounding plaques, as contributors
to modifications of synapses in AD [16–18]. Complete un-
derstanding of these synaptic abnormalities, and the asso-
ciated mechanism(s), could allow for the development of
potential therapeutics that would delay, prevent or reverse
synaptic changes in the disease process. Lectican-
containing ECM around the synapse may function to in-
hibit synaptic plasticity. Further, the elevation of lecticans
in AD and aging suggests this matrix has the potential to
contribute to diminished synaptic plasticity [19, 20]. Inter-
estingly, a recent study demonstrated that injection of
ChABC in young AD model mice identified to have ele-
vated lectican levels resulted in a reversal of contextual
fear memory deficits and a restoration to normal long
term potentiation [21].
Given these previous reports, this study aimed to
examine whether intra-hippocampal administration of
ChABC could ameliorate the loss of synaptic density
surrounding Aβ-containing plaques in the hippocam-
pus. For these experiments we utilized the APPswe/
PS1dE9 model, a mouse shown to have substantial syn-
aptic deficits with age [22]. While previous evidence
demonstrated that CS-bearing PGs (derived from cartil-
age) can interact with and bind to Aβ, we also deter-
mined whether Aβ binds to PGs purified from mouse
brains, and how this interaction might affect the depos-
ition of Aβ into senile plaques in this model.
Materials and Methods
Human tissues and western blot
Superior frontal cortical tissue was obtained from the
Rush Alzheimer’s Center, Rush Medical Center
(Chicago, IL) from subjects with no cognitive impair-
ment (NCI, n = 14, mean age 83.0 years, post-mortem
interval 10.2 h), subjects with mild cognitive impair-
ment (MCI, n = 10, mean age 88.4 years, post-mortem
interval, 7.1 h), and AD subjects (n = 14, mean age
90.1 years, post-mortem interval 8.8 h). Distribution of
age and gender was comparable among the three
groups and neuropathological assessment was based on
Braak score, CERAD diagnosis and NIA/Reagan Diagnosis
(for details, see Additional file 1: Table S1). Frozen tissue
was extracted in RIPA buffer (50 mM Tris, 150 mM NaCl,
2 mM EDTA, 1 % Triton-X-100, 1 % sodium deoxycho-
late, 0.1 % SDS, pH 7.4; all components from Sigma
Aldrich, Saint Louis, MO) with protease inhibitor cocktail
III (Calbiochem, LaJolla, CA). Western blots were con-
ducted as previously described [23]. Briefly, sample ex-
tracts were diluted with 2x Laemmli buffer, heated at 95 C
for 4 min and loaded onto 4-20 % gradient SDS-PAGE
gels (Life Technologies, Carlsbad, CA), electrophoresed,
transferred to PVDF membrane (Immobilon, EMD
Millipore, Billerica, MA), and probed consecutively
using standard antibody techniques. The primary
antibodies used were goat anti-brevican (1:500, Santa
Cruz Biotechnology sc-20555, Dallas, TX) and monoclonal
rabbit anti-GAPDH (1:5000; Cell Signaling 5174, Beverly,
MA). The blots were then incubated with donkey anti-goat
IgG and goat anti-rabbit IgG conjugated to horseradish
peroxidase (HRP, 1:20,000; EMD Millipore), the antigens
visualized with Immobilon Western Chemiluminescent
HRP substrate (EMD Millipore), and the blots were
exposed to autoradiographic film (Denville Scientific,
Metuchen, NJ). The film was scanned with an Epson
Perfection V700 photo scanner (Epson, Long Beach, CA).
Density of the bands were quantified using Image Studio
software 4.0 (Li-Cor, Lincoln, NE). The density of the sam-
ples were divided to make a proportion of the internal con-
trol sample that was included on each gel. Then these were
converted to a ratio of the GAPDH density (also as a meas-
ure of the internal control) from the same sample.
Preparation of monomeric, oligomeric and fibrillar Aβ1-42
Synthetic Aβ1-42 and Aβ1-16 was purchased (American
Peptide Company, Sunnyvale, CA), solubilized with
1 mM hexafluoro-2-propanol (HFIP; Sigma Aldrich), ali-
quoted into separate tubes and allowed to evaporate
under a chemical hood followed by speedvac to ensure
complete removal of solution, and subsequently stored
at −20 C. To obtain monomeric Aβ1-42 and Aβ1-16, the
peptide film was diluted to 1 mM with dimethylsulfoxide
(DMSO) and subjected to brief bath sonication. The so-
lution was then stored at −20 C. For oligomeric Aβ1-42,
the peptide solubilized in 1 mM DMSO was diluted to
100 μM with ice cold phosphate-buffered saline (PBS)
and placed at 4 C for 18 h or 42 h and immediately
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used. For fibrillar Aβ1-42, peptide solubilized in 1 mM
DMSO was diluted to 100 μM with PBS, incubated in a
37 C water bath for 48 h, and then stored at −20 C for
future use.
Aβ binding assays, DEAE purification of brain tissue,
immunoprecipitation
Soluble extracts were prepared from whole wild type
C57Bl/6 mouse brain and purified on a diethylami-
noethyl (DEAE) Fast Flow column (GE Healthcare Life
Sciences, Pittsburgh, PA) with sequential elution with in-
creasing concentrations of NaCl as described [24, 25].
This method generates an extract enriched with CS-
containing proteins. This extract was used for a solid-
phase binding assay to determine potential binding with
Aβ1-42 and Aβ1-16 using modification of a previously
described protocol [26]. Wells of 96-well plates were
coated with 5 μg protein/50 μl of the DEAE extract
diluted in PBS and the plate was incubated overnight at
4 C. Wells were washed three times with PBS and then
incubated in blocking buffer (2 % bovine serum albumin
[BSA; Sigma-Aldrich] in PBS) for two hours with min-
imal shaking. Wells were washed once with PBS and
100 μl of the appropriate concentration and conform-
ation of Aβ1-42 or Aβ1-16 was added and the plates in-
cubated at room temperature for 2 h. Wells were then
washed three times with PBS and mouse anti-Aβ 4G8
(Covance; Dallas, TX) or mouse anti-Aβ 6E10 (Covance)
diluted 1:2000 was added in blocking solution. After pri-
mary antibody addition, wells were washed three times
with PBS and 100 μl of goat anti-mouse IgG conjugated
to HRP (1:2000; Thermo Scientific, Rockford, IL) was
added and the plate incubated for 1 h at room
temperature. After washing, TMB substrate (Sigma-
Aldrich) was added and wells were allowed to de-
velop until the blank wells turned faint blue, and the
reaction was stopped by adding 50 μl 1 M sulfuric
acid. Absorption was read at 450 nm.
The same DEAE extract as described above was used
for immunoprecipitation experiments. Briefly, 10 μg of
DEAE extract was incubated with 2 μg of monomeric,
oligomeric, or fibrillar Aβ1-42 in 1 ml of PBS containing
1 % BSA. Assuming that brevican is ~1/50th of total
DEAE, the concentration of brevican was ~1 nM with
444 nM Aβ1-42. The tubes were incubated at room
temperature for 2 h, and then 5 μg of mouse anti-Aβ
4G8 (Covance) was added and incubation continued for
1 h. Washed and equilibrated Protein A Sepharose 4B
beads (GE Healthcare Life Sciences) were added to the
solution and incubated for 30 min with vortexing every
5 min. The beads were centrifuged, washed with 1 %
BSA in PBS and 40 μl of 2x Laemmli sample buffer was
added to the beads, incubated for 10 min with vortexing,
centrifuged and supernatant recovered. For western blot,
30 μl of each sample was loaded onto 4-20 % SDS-
PAGE gels, electrophoresed, transferred to PVDF
membrane and probed with mouse anti-brevican (BD
Biosciences 610895, San Jose, CA).
Mice and surgery
Mouse protocols used in these experiments were
approved by the Institute for Animal Care and Use
Committee at the University of Arkansas for Medical
Sciences and effort was made to limit the number of
animals required in each experiment and any pain pro-
duced by the surgery. B6C3-Tg(APPswe,PSEN1dE9)85Dbo
mice (APPswe/PS1dE9) were purchased from Jackson
Laboratory (Bar Harbor, MN) and a live colony was
maintained in our local vivarium by mating hemizy-
gotes with nontransgenic animals. Litters from these
matings were used for both non-transgenic controls
and APPswe/PS1dE9 mice. Mice were aged to 14
months and then underwent surgery for brain injection
of chondroitinase ABC (ChABC; Sigma Aldrich, St.
Louis, MO). Mice were anesthetized with inhaled iso-
flurane and mounted on a Kopf stereotaxic apparatus
(Tujunga, CA) with a specialized nose cone to accom-
modate brain surgery. The body was placed on a heat-
ing pad, the head sterilized and shaved, an incision
made at the sagittal midline, and a hole was made in
the skull using a high speed drill. A 1 μl injection of ei-
ther ChABC (5 mU/μl), diluted in saline containing
0.1 % BSA, or saline with 0.1 % BSA was made using a
10 μl Hamilton syringe with a 32 gauge blunt end nee-
dle to the following site at the right dorsal hippocam-
pus (distance in mm from bregma: posterior 1.8 mm,
lateral 1.2 mm, ventral 1.2 mm). The injection was
made over a two minute span and after the completion
of the injection the needle was held in place for an
additional two minutes. The needle was then removed,
the hole closed with bone wax, the incision sutured,
and the animal returned to a cage containing a heating
pad for 30 min and then back to the regular cage.
Eighteen days after surgery, mice were euthanized with
pentobarbital and cardiac-aorta perfused with ice cold
saline followed by 4 % paraformaldehyde. The brain
was dissected and fixed overnight at 4 C in 4 % parafor-
maldehyde (Sigma-Aldrich). Prior to cryostat section-
ing, the brains were incubated in 15 % and 30 %
sucrose prepared in PBS. For detection of the length of
time that ChABC reduces Wisteria floribunda agglu-
tinin (WFA) staining (Fig. 3), four month old C57Bl/6
mice were injected with the same dose of ChABC and
euthanized 1, 2 and 3 weeks following surgery, their
brain collected and processed for histochemistry as de-
scribed above. Sections were stained with WFA (Vector
Laboratories, Burlingame, CA).
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Measurement of Aβ burden and synaptic density in
stratum lacunosum moleculare (slm)
Free floating, 30 μm cryostat sections underwent im-
munofluorescence staining using standard protocols as
described [24] with rabbit anti-Aβ 95-2-5; [24, 27–29],
mouse anti-synaptophysin (MAB368; EMD Millipore)
and mouse anti-PSD-95 (clone K28/74 Ab2315909;
Neuromab, Davis, CA). Fluorescent secondary antibodies
used were: goat anti-rabbit IgG conjugated to Alexa Fluor
594 (anti-Aβ) and goat anti-mouse IgG conjugated to
Alexa Fluor 488 (anti-synaptophysin and anti-PSD-95). For
each mouse, three sections were analyzed beginning with a
random section where the lateral ventricles end at the ven-
tral hippocampus, and the next two sections were each
separated by 120 μm. Aβ burden was conducted on Aβ
and PSD-95 stained sections and images were captured of
the contralateral and ipsilateral (injected hemisphere)
hippocampus at 100x magnification. Images were opened
in Fiji Image J and the slm was outlined on the PSD-95
image. This outline was then transferred to the Aβ-stained
image. Brightness, contrast and threshold was adjusted
identically for all sections and the “area fraction” occupied
by Aβ staining in the binary image was calculated. This
was performed on both the contralateral and ipsilateral
slm of ChABC injected sections (7 mouse brains, 3 sec-
tions each), as well as vehicle injected sections (3 mouse
brains, 3 sections each).
Sections to measure synaptic density surrounding pla-
ques in the slm were stained with anti-Aβ and anti-
synaptophysin with the same secondary antibodies. Synap-
tophysin density was measured with similar distribution of
sections. Plaques were identified in the slm and images
were adjusted for brightness and contrast that was used in
an identical manner for every section. The Aβ image was
magnified to 150 % of the original; using the freehand se-
lection tool on Image J, a freehand shape was drawn
around the most intense region of the plaque. Once
complete, the synaptophysin image was selected, and the
“Restore Selection” command (Edit→Selection→Restore
Selection) was used to move the freehand drawing onto
the synaptophysin image in the identical location and
density measured. The drawing was then moved to a simi-
lar non-plaque area in the un-injected hippocampus,
density measured, and the density of the plaque was di-
vided by the density of the non-plaque region. This pro-
cedure was then repeated for a region outside the intense
region of the plaque and then a region that is ½ the width
of the distance between the two previous freehand draw-
ings. Thus, the y-axis term “Proportion of non-plaque
density” in Fig. 5 refers to the ratio of synaptophysin dens-
ity of the plaque region divided by the synaptophysin
density of the non-plaque region. This proportion was cal-
culated for the “inner”, “middle” and “outer” regions of the
plaque.
Statistical analysis
All analyses were performed using GraphPad Prism 5.0.
p < 0.05 was considered a significant difference unless
stated otherwise. Brevican density from human tissue on
Western blots was evaluated by one way ANOVA
followed by Bonferroni multiple comparison test. (NCI
n = 14, MCI n = 10, AD n = 14). EC50s for the binding
assays were determined with non-linear regression. The
mean EC50s (n = 5 binding assays) for multiple con-
formational Aβ binding to DEAE purified brain protein
was evaluated using one-way ANOVA followed by
Tukey’s multiple comparison test. For Aβ burden the
per cent area occupied and per cent ipilateral to per cent
contralateral comparisons were performed using un-
paired Student’s t-test (n = 7 per group). Evaluation of
synaptophysin density was performed using one-way
ANOVA followed by Tukey’s multiple comparison test.
Significant difference between groups are listed as p < 0.05
or p < 0.01.
Results
Increasing evidence has demonstrated that CS-bearing
ECM molecules increase with age [20] and are associ-
ated with AD [19]. Thus, we assessed brevican content
in superior frontal gyrus from no cognitive impairment
(NCI), mild cognitive impairment (MCI) and Alzheimer’s
disease (AD) subjects using immunoblot (for full
blots, see Additional file 2: Figure S1). A clear eleva-
tion of intact, full-length brevican core protein con-
tent (Fig. 1a, arrow) was observed in AD superior
frontal gyrus tissue compared to NCI individuals
(Fig. 1a, b). Indeed, brevican in AD frontal gyrus was
nearly double that of NCI tissue, and there was a
clear trend of increased full length brevican in MCI
subjects compared to NCI tissue.
Previous data has also shown that CS-bearing PGs
bind to Aβ, but it is not known whether Aβ binds to
brain-derived lecticans [10, 30]. Binding of Aβ to lecti-
cans may enhance the inhibition of synaptic plasticity.
Thus, an extract enriched with CS-bearing PGs was
purified from whole mouse brain and this extract was
used to perform a solid-phase binding assay with various
forms of Aβ (Fig. 2a and b). We observed a dose-
dependent increase in monomeric, oligomeric, and fibril-
lar Aβ1-42 binding to the DEAE extract (Fig. 2b). The
EC50 for monomeric was 1.6 ± 0.12 μM, oligomeric was
2.4 ± 0.2 μM, and fibrillar was 2.7 ± 0.3 μM for variants
of Aβ1-42 and 50.0 ± 3.0 μM for Aβ1-16. All three con-
formations of Aβ1-42 showed significantly higher affinity
binding to CS-bearing PGs compared to Aβ1-16 (n = 5
assays; p < 0.05). Interestingly, when conducting soluble
binding of various forms of Aβ1-42 with DEAE extract,
immunoprecipitating with anti-Aβ antibody and probing
for brevican on a Western blot, oligomeric and fibrillar
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Aβ showed greater binding to brevican compared to
monomeric Aβ1-42 (Fig. 2c), although there was binding
by all three forms.
Since it was demonstrated that Aβ and brain-derived
lecticans do interact, it was next examined whether re-
moval of CS chains from the lecticans would affect the
presence of Aβ-containing plaques and the presence of
a synaptic marker surrounding these Aβ plaques.
Stereotaxically-positioned, APPswe/PS1dE9 and non-
transgenic (nt) mice were injected with 5 mU of
ChABC at 14 months of age at a location that was at
the most dorsal hippocampus, on the ventral side of
the corpus callosum. Previous studies have shown that
a single injection of ChABC results in long-lasting re-
moval of CS chains from a large region of the target
area [31, 32]. Indeed, staining brain tissue from 3
months old mice that were previously injected with
ChABC with Wisteria floribunda agglutinin (WFA, a
lectin that detects carbohydrate structures that contain
N-acetylgalactosamine and stains perineuronal nets
Fig. 1 Western blot of human brevican from superior frontal gyrus of subjects with NCI (no cognitive impairment), MCI (mild cognitive
impairment) and AD (Alzheimer’s disease). a Brevican blot of one lane from each group with intact brevican indicated by the arrow and
GAPDH inset for normalization. b Quantification of intact brevican band density as a proportion of GAPDH density. Data were subject to
one way ANOVA followed by Bonferroni multiple comparison test. Level of AD brevican is significantly elevated (p < 0.05) compared to
NCI; (NCI n = 14, MCI n = 10, AD n = 14)
Fig. 2 Binding of Aβ isoforms to DEAE purified molecules including brevican. a. Western blot of Aβ isoforms used in binding assay to DEAE
products in “b”. b. Solid phase, dose-dependent, binding of Aβ1-42 isoforms (monomeric, oligomeric and fibrillar) and Aβ(1–16) to DEAE purified
molecules. The mean EC50s (n = 5 binding assays) for multiple conformational Aβ binding to DEAE purified brain protein was evaluated using
one way ANOVA followed by Tukey’s multiple comparison test. EC50 for monomeric, oligomeric and fibrillar Aβ1-42 is significantly lower compared to
the EC50 for Aβ1-16; (p < 0.05). c. Immunoprecipitation of brevican with mouse anti-Aβ 4G8 after soluble binding to DEAE product. Western blot was
performed with mouse anti-brevican antibody. Lane identities: lane 1 DEAE extract only; lane 2 fibrillar Aβ only; lane 3 4G8 antibody only; lane 4 DEAE
extract +monomeric Aβ; lane 5 DEAE extract + oligomeric Aβ; lane 6 DEAE extract + fibrillar Aβ. Anti-Aβ 4G8 pulled down brevican bound to oligo-
meric (lane 5) and fibrillar Aβ (lane 6). Lower molecular weight bands correspond to heavy and light IgG chains. Although all three isoforms of Aβ1-42
bound to brevican, binding to monomeric Aβ was markedly lower than binding to oligomeric and fibrillar Aβ
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[PNNSs] in brain) indicated a long-lasting decrease of
WFA staining in the injected hemisphere (Fig. 3). A sig-
nificant amount of cortex and a majority of the dorsal
hippocampus showed a reduction in WFA of staining,
an effect that persisted for at least 3 weeks following in-
jection (Fig. 3). Thus, injection of ChABC into AD
model tissue allows for evaluation of the effect of re-
moval of CS on Aβ deposition into plaques and deter-
mination of this effect on synaptic density in regions
surrounding these plaques.
In APPswe/PSdE9 mice, 18 days after ChABC injec-
tion Aβ burden was measured in the stratum lacuno-
sum moleculare (slm), one region of the hippocampus
that contains numerous amyloid plaques. The slm was
easily recognized when co-staining the sections for
PSDS-95 (Figure 4ad and ad’). The reduction in Aβ
plaques was observable in the ChABC-treated hemisphere
(eg. Figure 4aa). The per cent of the slm occupied by Aβ
after thresholding the immunoreactive density (Figure 4ae)
was nearly 50 % lower in ChABC treated slm compared to
the non-ChABC treated slm hemisphere (Fig. 4b, left
graph; p < 0.05). When the ratio of ipsilateral/contralateral
was calculated and compared to vehicle-treated APPswe/
PS1dE9 mice, there was approximately a 40 % reduction
in Aβ burden. Thus, removal of CS for 18 days after injec-
tion of ChABC resulted in a significant reduction in the
presence of Aβ in the slm hippocampus in APPswe/
PS1dE9 mice.
Since ChABC significantly reduced Aβ plaque burden in
the slm, it was next examined whether synaptic density
surrounding the plaques was altered. Additional sections
containing hippocampus from the same ChABC-treated
mice were subjected to immunofluorescence for Aβ and
synaptophysin. On the Aβ image, free hand rings were
drawn around regions of the highest plaque density, the
less dense “halo” area and then about 50 % of the distance
from the first to the second ring (Figure 5aa). The rings
were then moved to the synaptophysin stained image of
the same section (Figure 5ab) and the density of each ring
was determined. The rings were then moved to a “non-
plaque” region adjacent to the plaque (Figure 5ac) and the
density was measured and calculated on each ring to de-
termine the plaque/non-plaque ratio. In an initial experi-
ment prior to ChABC treatment, there was a significant
decrease in synaptophysin density ratio in the middle
and inner rings, compared to the outer ring (Fig. 5b).
When the same experiment was conducted with
ChABC injected animals, there was again a significant
difference in synaptophysin density ratio between the
middle and outer rings around plaques measured in the
slm of the un-injected, contralateral hemisphere
(Fig. 5c). However, there was no significant difference
in the density of the middle and outer rings in the
ChABC injected region (Fig. 5d). These data suggest
that some mechanism related to the removal of CS
chains was responsible for inducing synaptic plasticity
that increased synaptophysin density in the middle
region.
Fig. 3 Intracerebral ChABC injection results in a marked and
long-lasting decline in CS-bearing PGs. Low magnification
micrographs (25x) of Wisteria floribunda agglutinin (WFA) staining
1, 2, and 3 weeks after ChABC injection (5 mU/1 μL). Arrowhead
represents injection site for ChABC. Note the widespread loss of
WFA immunoreactivity in the injected (left side) cortex and
hippocampus (area with white outline). Injection target was to
the ventral side of the corpus callosum on the dorsal side of
dorsal hippocampus
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Fig. 4 (See legend on next page.)
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Discussion
The results from this study have shown that intracere-
bral injection of ChABC into 15 months old APPswe/
PS1dE9 mice increased synaptic density surrounding
plaques and reduced Aβ burden in the slm of the
hippocampus. Although the increase in synaptophysin
density surrounding plaques in the slm of ChABC
injected animals was quite modest, it was significantly
different from the uninjected hemisphere. We demon-
strated that Aβ binds to brain-derived lecticans,
Fig. 5 ChABC injection increases density of synaptophysin surrounding Aβ plaques in the slm. aa. freehand rings were drawn around three
regions of an amyloid plaque (inner, middle and outer). ab. rings were transferred to the identical location on the synaptophysin image and
density measured in each ring. ac. identically drawn rings were moved to an adjacent, non-plaque region and synaptophysin density measured.
b. quantitative density measurements of synaptophysin immunoreactivity around plaques in slm of 15 months old APPswe/PS1dE9 mice.
Measurements were made in the slm after ChABC injection on the (c) contralateral, non-injected hemisphere and the (d) injected, ipsilateral side.
The y-axis term “Proportion of non-plaque density” refers to the ratio of synaptophysin density of the plaque region divided by the synaptophysin
density of the non-plaque region. This proportion was calculated for the “inner”, “middle” and “outer” regions of the plaque. Note there was a
significant loss of synaptophysin immunoreactivity between the outer and middle plaque layers on the contralateral (c) but not inpsilateral,
ChABC-injected side (d). For (b) n = 5 mice, for (c) and (d) n = 7 mice, * p < 0.05; ***p < 0.001
(See figure on previous page.)
Fig. 4 Injection of ChABC into APPswe/PS1dE9 dorsal hippocampus results in reduced amyloid burden in the stratum lacunosum moleculare
(slm). aa. Immunostaining for Aβ (rabbit anti-Aβ 95-2-5) showing whole brain section of ChABC injected APPswe/PS1dE9 mouse hippocampus at
low magnification (25x); ab,ab’. Aβ immunostaining of slm on ChABC injected ipsilateral (ab) and contralateral (ab’) sides (100x). ac,ac’. inverted
images of (ab and ab’). ad,ad’. PSD-95 staining in the same sections as in (ac,ac’) with slm outlined in blue. ae,ae’. sections from (ac,ac’) thresholded and
converted to binary to calculate the area occupied by Aβ. b. Quantitative measurement of area occupied by Aβ in the slm as area occupied by Aβ
(left graph; APPswe/PS1dE9 n = 7) and area occupied as per cent of contralateral side (right graph, no ChABC treatment n = 3; ChABC treatment n = 7).
Comparison between treatments was made using unpaired Student’s t-test. *p < 0.05 was considered a significant difference between groups
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including brevican, molecules known to be involved in
inhibition of synaptic plasticity. Since lecticans are ele-
vated in AD frontal cortex brain tissue [19], this finding
suggests that lecticans may play a role in diminishing
synaptic plasticity in AD tissue. This role most likely in-
volves brevican, since it is a lectican that is deposited as
an extracellular, adjacent synaptic protein [6, 33]. Ac-
cordingly, the targeting of lecticans at the synapse could
be a beneficial direction for eventual therapeutic devel-
opment for AD.
The role of CS-bearing PGs in synaptic plasticity has
been known for nearly two decades. It was originally
demonstrated that alterations in deposition occurred in
visual cortex following visual deprivation [34]. The abil-
ity of ChABC treatment to reinstate ocular dominance
plasticity in a visually-deprived adult animal was the
first result that implicated these PGs in nervous system
plasticity [7]. More recent data has shown that PGs
contribute to the stability of various learning and mem-
ory behaviors and that ChABC treatment can enhance
plasticity for recall [9, 35]. In addition, levels of hippo-
campal brevican and versican were increased in rats ex-
posed to training in the Morris water maze, and
immunoprecipitation of brevican and versican demon-
strated that these lecticans bind to the GluR1 subunit
of the AMPA receptor [36]. Thus, the major loss of
synaptic plasticity in progressive AD is presumed to be
due to the pathological functions of Aβ and tau [37];
however, it is possible that CS-bearing PGs may have
some input into the process as well. There have been
two prior studies that have examined how treatment
with ChABC can induce plasticity in brain of AD model
mice. One study demonstrated that young, 3 months
old APPswe/PS1dE9 mice that had not developed pla-
ques had elevated matrix protein levels, an impaired
ability to form contextual fear memory, and a decline
in hippocampal long term potentiation [21]. Hippocam-
pal injection of ChABC reinstated both fear memory
behavior and long term potentiation [21]. Interestingly,
matrix proteins were not significantly elevated in 6 or
12 months old APPswe/PS1dE9 mice. This finding sug-
gests that elevated lecticans may play a role in the early
memory loss in this model. Data from the current study
adds to this hypothesis, where even in aged APPswe/
PS1dE9 mice, ChABC treatment induced synaptic plas-
ticity in regions that surround plaques in the slm of the
hippocampus. These regions surrounding plaques have
been shown to contain elevated levels of soluble oligo-
meric Aβ that associates with post-synaptic densities
[38]. It would be interesting to determine whether there
is an interaction of Aβ with CS-bearing PGs such as
brevican in these adjacent synaptic regions that are
near senile plaques. In two different mouse models of
tau pathology, although ChABC treatment did not
affect the progression of the neurodegenerative disease
state, it did restore plasticity by reversing the decline in
synaptic transmission and improved object recognition
memory in both models [39]. Although classically tau
has been thought of as an axonal microtubule-related
protein, more recent data indicates that it is more
widely distributed in neurons and in AD tissue, a trun-
cated fragment of tau may be secreted from pre-
synaptic terminals [18]. Thus, ChABC may be exerting
its action at the synapse in the tauopathy models as
well.
Unique to this study is the observation that over time,
the removal of CS chains in the CNS by intracerebral
administration of ChABC reduces Aβ bearing plaques
and plaque size in APPswe/PS1dE9 mice hippocampus.
It is known that the formation of Aβ42 bearing fibrils is
enhanced in the presence of polymeric glycosaminogly-
cans [40] and most importantly, the binding of Aβ42 to
glycosaminoglycans increased the resistance of Aβ42 to
proteolysis 2 to 5-fold; these findings suggested that
elimination of CS chains in AD models brain should
reduce plaques by enhancing the degradation of Aβ42
[26, 40]. The present data supports this hypothesis in a
heavy plaque-bearing region of the hippocampus, the
slm, in ChABC-treated APPswe/PS1dE9 mice. In fact, a
single intra-hippocampal injection reduced Aβ load by
almost 50 % 18 days after injection. Thus, ChABC injec-
tion may be beneficial in stimulating plasticity, as well as
reducing Aβ burden.
Substantial supporting evidence suggests that not
only can CS-bearing PGs exert negative actions on
plasticity mechanisms in models of neurodegenerative
disease, but that other areas of expression of these
agents may be quite beneficial. Significant evidence ex-
ists that suggests that aggregates of matrix lattice that
include lecticans, hyaluronic acid and tenascin-R, that
exist as PNNs are protective toward neuronal cell bod-
ies. Indeed, under several neurodegenerative conditions
in vivo and in vitro, the presence of CS-bearing PGs
and/or PNNs have been shown to be neuroprotective
[30, 41–44]. In AD brain, neurons in cortical regions
bearing matrix PNNs were less affected by neurofibril-
lary tangle pathology [3]. Indeed, tau pathology was lo-
cated in CNS regions with a low proportion of neurons
with PNNs, and overall no changes were observed in
numbers or structure of PNNs [45, 46, 47]. One study
implicated that increases in brevican and cartilage link
protein in AD may exist in functional peri-synaptic re-
gions, a hypothesis requiring further support [19].
These data provide the insight that not only do PNNs
potentially protect neurons from cell death in AD, but
that perisynaptic matrix maintains synapse integrity in
neurodegenerative disease. The present findings most likely
support the notion that the presence of perisynaptic matrix
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contributes to the inhibition of synaptic plasticity in AD,
and that removal of CS chains from this matrix would
stimulate plasticity.
Future studies may focus on defining the mechanism
of CS-bearing PGs involvement in neuroprotection and
synaptic plasticity. Most of these studies have been con-
ducted with differential means of altering the expression
or structure of CS-bearing PGs. Although it is evident
that CS on these core proteins is clearly important in in-
hibition of synaptic plasticity, the contribution of CS or
the larger matrix aggregate in the neuroprotective prop-
erties remains to be distinguished.
Conclusions
Hippocampal injection of ChABC in the APPswe/
PS1dE9 mouse model of AD resulted in reduced amyloid
burden and increased synaptic marker density surround-
ing plaques in the slm of the hippocampus. This sug-
gests that because brevican binds to Aβ, the reduction in
Aβ and loss of CS chains from brevican located in syn-
aptosomal regions may enhance synaptic plasticity. En-
hancing synaptic plasticity in early AD, either with
ChABC treatment or by reductions in brevican signaling
may be a significant target that could slow disease
progression.
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